Relationships between selenium, lipids, iron status and hormonal therapy in women of the SU.VI.M.AX cohort.
Significant differences in serum selenium concentration according to contraceptive treatment and age have been evidenced in women of the SU.VI.M.AX cohort. This study aimed at verifying the physiopathological hypothesis that the observed increase in serum selenium concentration could be related to serum lipid increase and/or bleeding decrease. Women were divided into six groups: menopausal with or without hormonal replacement therapy; non-menopausal using contraceptive pills; intrauterine device; other contraceptive treatment or no contraceptive treatment. Adjusted linear regression indicated positive associations between selenium and apolipoprotein A1 (r(2) from 0.038 to 0.074, p<0.07 depending on groups) or ferritin in serum (r(2) from 0.032 to 0.075, p<0.07 depending on groups). These relationships could explain the differences observed according to hormonal treatment and age in the SU.VI.MAX study.
Arnaud
Josiane
J
Département de Biologie Intégrée, Pôle de biologie, CHU de Grenoble, BP 217, 38043 Grenoble Cedex 9, France. JArnaud@chu-grenoble.fr
Arnault
Nathalie
N
Roussel
Anne-Marie
AM
Bertrais
Sandrine
S
Ruffieux
Daniel
D
Galan
Pilar
P
Favier
Alain
A
Hercberg
Serge
S
D000328:Adult; D000368:Aged; D015331:Cohort Studies; D003271:Contraceptive Agents, Female / Q000494:pharmacology*; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D007501:Iron / Q000097:blood*; D050356:Lipid Metabolism / Q000187:drug effects*; D008593:Menopause; D008875:Middle Aged; D012643:Selenium / Q000097:blood*
D003271:Contraceptive Agents, Female; D007501:Iron; D012643:Selenium